Patents by Inventor Matthew Riese

Matthew Riese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
    Patent number: 11931380
    Abstract: The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: March 19, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Steven M. Albelda, Liang-Chuan Wang, Gary Koretzky, Matthew Riese
  • Inhibition of Diacylglycerol Kinase to Augment Adoptive T cell Transfer
    Publication number: 20210236553
    Abstract: The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
    Type: Application
    Filed: April 14, 2021
    Publication date: August 5, 2021
    Inventors: Steven M. ALBELDA, Liang-Chuan WANG, Gary KORETZKY, Matthew RIESE
  • Inhibition of Diacylglycerol Kinase to Augment Adoptive T cell Transfer
    Publication number: 20190008898
    Abstract: The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 10, 2019
    Inventors: Steven M. ALBELDA, Liang-Chuan WANG, Gary KORETZKY, Matthew RIESE
  • Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
    Patent number: 9937205
    Abstract: The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: April 10, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Steven M. Albelda, Liang-Chuan Wang, Gary Koretzky, Matthew Riese
  • INHIBITION OF DIACYLGLYCEROL KINASE TO AUGMENT ADOPTIVE T CELL TRANSFER
    Publication number: 20150224142
    Abstract: The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.
    Type: Application
    Filed: September 4, 2013
    Publication date: August 13, 2015
    Inventors: Steven M. Albelda, Liang-Chuan Wang, Gary Koretzky, Matthew Riese